Kuros Biosciences Ltd.
Develops biologic technologies for tissue repair and bone regeneration.
KURN | SW
Overview
Corporate Details
- ISIN(s):
- CH0325814116
- LEI:
- 5299006U5POB2AVTT709
- Country:
- Switzerland
- Address:
- Wagisstraße 25, 8952 Schlieren
- Website:
- https://kurosbio.com/
- Sector:
- Manufacturing
Description
Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-02-21 07:00 |
Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for …
|
English | 16.1 KB | ||
| 2023-02-21 01:00 |
Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for …
|
English | 13.8 KB | ||
| 2023-02-16 18:01 |
Kuros Biosciences Announces Changes to Executive Management Team
|
English | 11.8 KB | ||
| 2023-02-16 01:00 |
Kuros Biosciences Announces Changes to Executive Management Team
|
English | 9.7 KB | ||
| 2022-11-23 07:00 |
Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for…
|
English | 14.1 KB | ||
| 2022-11-23 01:00 |
Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for…
|
English | 12.1 KB | ||
| 2022-11-02 07:00 |
Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Gra…
|
English | 15.3 KB | ||
| 2022-11-02 01:00 |
Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Gra…
|
English | 13.2 KB | ||
| 2022-10-26 07:00 |
Kuros reports 73% increase in MagnetOs sales in first nine months of 2022
|
English | 18.3 KB | ||
| 2022-10-26 02:00 |
Kuros reports 73% increase in MagnetOs sales in first nine months of 2022
|
English | 16.2 KB | ||
| 2022-10-19 07:00 |
Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix …
|
English | 14.1 KB | ||
| 2022-10-19 02:00 |
Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix …
|
English | 12.2 KB | ||
| 2022-10-11 07:00 |
Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 A…
|
English | 20.1 KB | ||
| 2022-10-11 02:00 |
Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 A…
|
English | 18.6 KB | ||
| 2022-10-03 07:00 |
Kuros Biosciences Appoints Chris Fair as Chief Operating Officer
|
English | 11.2 KB |
Automate Your Workflow. Get a real-time feed of all Kuros Biosciences Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kuros Biosciences Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kuros Biosciences Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-23 | N/A | Executive member | Sell | None | 1,264,800.00 CHF |
| 2025-04-17 | N/A | Executive member | Sell | None | 13,344.49 CHF |
| 2025-03-18 | N/A | Non-Executive member | Buy | None | 38,200.00 CHF |
| 2024-12-11 | N/A | Executive member | Sell | None | 4,702,500.00 CHF |
| 2024-11-15 | N/A | Non-Executive member | Buy | None | 925,210.00 CHF |
| 2024-11-14 | N/A | Non-Executive member | Sell | None | 592,000.00 CHF |
| 2024-11-12 | N/A | Executive member | Sell | None | 13,890.86 CHF |
| 2024-09-25 | N/A | Executive member | Sell | None | 8,226,000.00 CHF |
| 2024-09-25 | N/A | Non-Executive member | Sell | None | 3,656,000.00 CHF |
| 2024-09-24 | N/A | Non-Executive member | Buy | None | 223,720.00 CHF |
Peer Companies
